The Cell-Cycle Control of Astrocytes and Astrocytomas

星形胶质细胞和星形细胞瘤的细胞周期控制

基本信息

  • 批准号:
    6369209
  • 负责人:
  • 金额:
    $ 21.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-07-15 至 2002-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This year, and in every year in the foreseeable future, 17,000 Americans will develop primary brain cancers. Of these, the most common tumor is astrocytoma. Of the 8,000 people to be diagnosed with astrocytoma, all will eventually die of their disease. The vulnerability of the astrocyte to transformation lies in its ability to re-enter the cell-cycle at any point in the life-time of an organism. In spite of the ability to proliferate, astrocytes are kept mostly quiescent, except in response to disease or trauma, where there is a concomitant neuronal loss. A number of years ago, we and others demonstrated that astrocyte proliferative control is effected by contact with neuronal membranes, although the precise molecular mechanism by which neurons exert this control has remained elusive. My laboratory has recently identified a receptor on the surface of the astrocyte, CD8 1, which is absolutely required for neuron-induced astrocyte cell-cycle arrest (see Preliminary Data, and appended manuscript for details). In this application, we propose a series of biochemical, molecular and cell biological experiments aimed at the identification and characterization of neuronal CD8 1 binding proteins. In addition, we will begin to query the astrocytic signaling mechanism following neuronal binding. Our findings for the requirement for astrocyte expressed CD8 1 for neuron-induced growth control takes on added significance, based on our observation that all of the astrocytoma cell lines we have examined to date have absolutely down regulated CD8 1 protein and message. To determine if CD8 1 expression can rescue the ability of these cells to respond to neuron-induced by cell-cycle arrest, we have expressed a CD8 1 -GFP fusion construct in the astrocytoma cell lines. The transfectants will be assayed for in vitro neuronal responsiveness, and in vivo tumor progression and metastasis in nude mice. In parallel with these experiments, we will continue a series of affinity chromatographic purification of neuronal membrane proteins that are active inhibitors of astrocyte proliferation. While we hope and anticipate that our two lines of inquiry on neuronal mediators of astrocyte growth control will converge, it is quite possible that we will identify separate, redundant mechanisms that are involved in maintaining CNS numerical homeostasis.
描述(由申请人提供):今年,并在每年的 在可预见的未来,将有17,000名美国人患上原发性脑癌。的 这些,最常见的肿瘤是星形细胞瘤。在8,000人中, 被诊断出患有星形细胞瘤,所有人最终都会死于这种疾病。的 星形胶质细胞对转化的脆弱性在于它能够 在生物体生命周期的任何时候重新进入细胞周期。尽管 在增殖能力方面,星形胶质细胞大多保持静止,除了在 对疾病或创伤的反应,其中伴随有神经元损失。一 几年前,我们和其他人证明星形胶质细胞增殖 控制是通过与神经元膜接触来实现的,尽管精确的 神经元发挥这种控制作用的分子机制仍然是难以捉摸的。 我的实验室最近发现了一种受体, 星形胶质细胞,CD 8 1,这是神经元诱导的星形胶质细胞所必需的 细胞周期阻滞(详见初步数据和随附手稿)。 在这个应用中,我们提出了一系列的生物化学,分子和细胞 生物学实验,旨在鉴定和表征 神经元CD 8 1结合蛋白。此外,我们将开始查询 神经元结合后的星形胶质细胞信号传导机制。我们的研究结果 星形胶质细胞表达CD 8 - 1对神经元诱导生长控制的需求 根据我们的观察, 迄今为止,我们检测的星形细胞瘤细胞系绝对下调了 CD 81蛋白与信息。为了确定CD 8 1表达是否可以挽救 这些细胞对细胞周期阻滞引起的神经元反应的能力,我们 已经在星形细胞瘤细胞系中表达了CD 8 1 -GFP融合构建体。的 将测定转染子的体外神经元反应性,和体内神经元反应性。 裸鼠的肿瘤进展和转移。与此同时, 实验中,我们将继续进行一系列的亲和层析纯化 神经元膜蛋白是星形胶质细胞 增殖虽然我们希望并期待我们的两条调查路线 星形胶质细胞生长控制的神经元介质将收敛,这是相当 我们可能会发现涉及到的独立的、冗余的机制, 维持中枢神经系统的数值稳态。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID E WEINSTEIN其他文献

DAVID E WEINSTEIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID E WEINSTEIN', 18)}}的其他基金

Optimization of GMAK to treat glioblastoma multiforme
GMAK 治疗多形性胶质母细胞瘤的优化
  • 批准号:
    7107363
  • 财政年份:
    2006
  • 资助金额:
    $ 21.55万
  • 项目类别:
Characterization of the role of hepcidin in the anemia of chronic disease.
铁调素在慢性病贫血中作用的表征。
  • 批准号:
    6975166
  • 财政年份:
    2004
  • 资助金额:
    $ 21.55万
  • 项目类别:
Clinical Evaluation of Portable Lactate Meter in Type Glycogen Storage Disease
便携式乳酸计在型糖原贮积病中的临床评价
  • 批准号:
    6975186
  • 财政年份:
    2004
  • 资助金额:
    $ 21.55万
  • 项目类别:
Assessment of abnormal glycogen synthesis as a cause of ketotic hypoglycemia
糖原合成异常作为酮症低血糖原因的评估
  • 批准号:
    6975121
  • 财政年份:
    2004
  • 资助金额:
    $ 21.55万
  • 项目类别:
Correlation of Markers of Metabolic Control with Complications in GSD.
代谢控制标志物与 GSD 并发症的相关性。
  • 批准号:
    6975165
  • 财政年份:
    2004
  • 资助金额:
    $ 21.55万
  • 项目类别:
Characterization of anemia of chronic disease in type l
l型慢性病贫血的特征
  • 批准号:
    6975167
  • 财政年份:
    2004
  • 资助金额:
    $ 21.55万
  • 项目类别:
Refinement of GM1416-a Drug to Treat Neurodegeneration
治疗神经退行性疾病药物 GM1416 的精制
  • 批准号:
    6590954
  • 财政年份:
    2003
  • 资助金额:
    $ 21.55万
  • 项目类别:
The Cell-Cycle Control of Astrocytes and Astrocytomas
星形胶质细胞和星形细胞瘤的细胞周期控制
  • 批准号:
    6665187
  • 财政年份:
    2001
  • 资助金额:
    $ 21.55万
  • 项目类别:
The Cell-Cycle Control of Astrocytes and Astrocytomas
星形胶质细胞和星形细胞瘤的细胞周期控制
  • 批准号:
    6762366
  • 财政年份:
    2001
  • 资助金额:
    $ 21.55万
  • 项目类别:
The Cell-Cycle Control of Astrocytes and Astrocytomas
星形胶质细胞和星形细胞瘤的细胞周期控制
  • 批准号:
    6540521
  • 财政年份:
    2001
  • 资助金额:
    $ 21.55万
  • 项目类别:

相似海外基金

Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10506915
  • 财政年份:
    2021
  • 资助金额:
    $ 21.55万
  • 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10325006
  • 财政年份:
    2021
  • 资助金额:
    $ 21.55万
  • 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
  • 批准号:
    1746198
  • 财政年份:
    2018
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
  • 批准号:
    512537-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 21.55万
  • 项目类别:
    University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
  • 批准号:
    1404605
  • 财政年份:
    2014
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
  • 批准号:
    1263713
  • 财政年份:
    2013
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
  • 批准号:
    425749-2012
  • 财政年份:
    2012
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
  • 批准号:
    1159886
  • 财政年份:
    2012
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
  • 批准号:
    19560760
  • 财政年份:
    2007
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
  • 批准号:
    234753-2000
  • 财政年份:
    2003
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了